
|Videos|December 27, 2022
RCC Trial Review: Checkmate 9ER
Author(s)Rana R. McKay, MD
Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































